D. Tural Et Al. , "Objective Response Rate is a Surrogate Marker for Long-Term Overall Survival in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors," CLINICAL GENITOURINARY CANCER , no.5, 2024
Tural, D. Et Al. 2024. Objective Response Rate is a Surrogate Marker for Long-Term Overall Survival in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors. CLINICAL GENITOURINARY CANCER , no.5 .
Tural, D., Arslan, C., Selcukbiricik, F., ÖLMEZ, Ö. F., ERMAN, M., ÜRÜN, Y., ... Erdem, D.(2024). Objective Response Rate is a Surrogate Marker for Long-Term Overall Survival in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors. CLINICAL GENITOURINARY CANCER , no.5.
Tural, Deniz Et Al. "Objective Response Rate is a Surrogate Marker for Long-Term Overall Survival in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors," CLINICAL GENITOURINARY CANCER , no.5, 2024
Tural, Deniz Et Al. "Objective Response Rate is a Surrogate Marker for Long-Term Overall Survival in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors." CLINICAL GENITOURINARY CANCER , no.5, 2024
Tural, D. Et Al. (2024) . "Objective Response Rate is a Surrogate Marker for Long-Term Overall Survival in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors." CLINICAL GENITOURINARY CANCER , no.5.
@article{article, author={Deniz Tural Et Al. }, title={Objective Response Rate is a Surrogate Marker for Long-Term Overall Survival in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors}, journal={CLINICAL GENITOURINARY CANCER}, year=2024}